Intracellular Therapies Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 955

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $14.6B

Intracellular Therapies General Information

Description

Developer of biopharmaceutical products intended to treat central nervous system disorders. The company utilizes an intracellular approach and medicinal chemistry to develop once-daily oral pills, antipsychotic medications, small-molecule drugs, therapeutics for schizophrenia, treatments for bipolar depression, and treatments for major depressive disorder, providing healthcare providers with targeted therapies for managing complex neuropsychiatric and neurological conditions.

Contact Information

Website
www.intracellulartherapies.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 135 Route 202/206
  • Suite 6
  • Bedminster, NJ 07921
  • United States
+1 (800)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Parent Company
Johnson & Johnson
Vertical(s)
Life Sciences
Corporate Office
  • 135 Route 202/206
  • Suite 6
  • Bedminster, NJ 07921
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intracellular Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Merger/Acquisition 02-Apr-2025 $14.6B Completed Generating Revenue
13. 2PO 18-Apr-2024 Completed Generating Revenue
12. 2PO 05-Jan-2022 Completed Generating Revenue
11. Secondary Transaction - Open Market Completed Generating Revenue
10. Grant 01-Jan-2019 Completed Generating Revenue
9. Secondary Transaction - Open Market Completed Generating Revenue
8. 2PO 05-Feb-2014 Completed Generating Revenue
7. PIPE 03-Sep-2013 Completed Generating Revenue
6. Reverse Merger 03-Sep-2013 $39.4M Completed Generating Revenue
5. Later Stage VC 25-Jun-2013 $15.3M $39.4M Completed Generating Revenue
To view Intracellular Therapies’s complete valuation and funding history, request access »

Intracellular Therapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical products intended to treat central nervous system disorders. The company utilizes an intr
Pharmaceuticals
Bedminster, NJ
955 As of 2025

Washington, DC
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intracellular Therapies Competitors (50)

One of Intracellular Therapies’s 50 competitors is Vanda Pharmaceuticals, a Formerly VC-backed company based in Washington, DC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vanda Pharmaceuticals Formerly VC-backed Washington, DC
Rigel Pharmaceuticals Formerly VC-backed South San Francisco, CA
Promentis Pharmaceuticals Venture Capital-Backed Milwaukee, WI
Anavex Life Sciences Corporation New York, NY
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 50 competitors. Get the full list »

Intracellular Therapies Patents

  • 1,457

    Total Documents Applications and Grants

  • Total Patents Families

  • 917

    Granted

  • 250

    Pending

  • Expiring in next 12 mo

Intracellular Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213364-A3 Lumateperone for use in the treatment of major depressive disorder Pending 01-Apr-2025
US-20260294901-A1 Methods for treating major depressive disorder comprising administering lumateperone Pending 01-Apr-2025
WO-2026213364-A2 Novel methods Pending 01-Apr-2025
WO-2026213323-A1 Organic compounds Pending 01-Apr-2025
WO-2026207350-A1 Organic compounds Pending 27-Mar-2025 A61P35/00
To view Intracellular Therapies’s complete patent history, request access »

Intracellular Therapies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intracellular Therapies Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alafi Capital Company Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
BB Biotech Asset Manager Minority
Broadfin Capital Hedge Fund Minority
Deerfield Management Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Intracellular Therapies ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

21.47 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Intracellular Therapies’s complete esg history, request access »

Intracellular Therapies FAQs

  • When was Intracellular Therapies founded?

    Intracellular Therapies was founded in 2002.

  • Where is Intracellular Therapies headquartered?

    Intracellular Therapies is headquartered in Bedminster, NJ.

  • What is the size of Intracellular Therapies?

    Intracellular Therapies has 955 total employees.

  • What industry is Intracellular Therapies in?

    Intracellular Therapies’s primary industry is Pharmaceuticals.

  • Is Intracellular Therapies a private or public company?

    Intracellular Therapies is a Private company.

  • What is the current valuation of Intracellular Therapies?

    The current valuation of Intracellular Therapies is .

  • What is Intracellular Therapies’s current revenue?

    The current revenue for Intracellular Therapies is .

  • How much funding has Intracellular Therapies raised over time?

    Intracellular Therapies has raised $1.18B.

  • Who are Intracellular Therapies’s investors?

    Alafi Capital Company, Alexandria Venture Investments, BB Biotech, Broadfin Capital, and Deerfield Management are 5 of 11 investors who have invested in Intracellular Therapies.

  • Who are Intracellular Therapies’s competitors?

    Vanda Pharmaceuticals, Rigel Pharmaceuticals, Promentis Pharmaceuticals, Anavex Life Sciences, and ACADIA Pharmaceuticals are some of the 50 competitors of Intracellular Therapies.

  • When was Intracellular Therapies acquired?

    Intracellular Therapies was acquired on 02-Apr-2025.

  • Who acquired Intracellular Therapies?

    Intracellular Therapies was acquired by Johnson & Johnson.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process